How Targeting Glutamine Addiction Could Revolutionize Basal Breast Cancer Treatment
Basal-like breast cancer cells are addicted to glutamine, and CB-839 effectively blocks their ability to use this essential nutrient, potentially starving tumors.
Imagine our bodies contain both carefully regulated energy distribution systems and rogue cells that secretly establish their own private power grids. This isn't science fiction—it's exactly how many cancers, particularly the aggressive basal-like breast cancer, survive and thrive. These cunning cells develop what scientists call "metabolic addiction"—they become dependent on specific nutrients to fuel their rapid growth.
Recent research has uncovered that many treatment-resistant cancers are addicted to glutamine, an amino acid that serves as their preferred energy source and building material. The search for ways to cut off this fuel supply has led to the development of CB-839 (Telaglenastat), an experimental drug that inhibits glutaminase—the key enzyme cancer cells need to utilize glutamine. This article explores how scientists are investigating this promising approach and why it represents a potentially groundbreaking strategy against one of the most challenging forms of breast cancer.
Cancer cells rewire their metabolism to depend on specific nutrients like glutamine for survival and growth.
An oral glutaminase inhibitor that blocks cancer cells' ability to process glutamine, potentially starving tumors.
For decades, we've known that cancer cells metabolize nutrients differently than healthy cells. The phenomenon, known as the Warburg effect, describes how cancer cells preferentially ferment glucose into lactate even when oxygen is available. But glucose isn't their only fuel source—many aggressive cancers develop an additional dependency on glutamine, the most abundant amino acid circulating in our bloodstream 5 .
Fuels the TCA cycle after conversion to glutamate and α-ketoglutarate
Provides building blocks for glutathione, protecting cells from damage
Supplies nitrogen for nucleotide and amino acid synthesis
The first and rate-limiting step in glutamine utilization is its conversion to glutamate, a reaction controlled by the mitochondrial enzyme glutaminase. Mammals have two main forms: GLS1 (expressed in most tissues) and GLS2 (primarily in the liver). Cancer cells predominantly overexpress GLS1, particularly the GAC splice variant that displays higher catalytic activity 5 . This discovery made GLS1 an attractive therapeutic target—if scientists could develop a drug to block this specific enzyme, they could potentially starve cancer cells of their favorite fuel without causing widespread damage to healthy tissues.
In a pivotal 2014 study published in Molecular Cancer Therapeutics, researchers conducted a comprehensive investigation of CB-839's effects across multiple laboratory models of breast cancer 1 . Their approach exemplifies the rigorous multi-step process required to validate potential anti-cancer therapies:
The team began by testing CB-839 on a panel of breast cancer cell lines representing different molecular subtypes, including triple-negative/basal-like breast cancer (TNBC) and estrogen receptor-positive (ER+) types.
They measured how CB-839 affected nutrient consumption, oxygen use, and metabolic intermediate levels in sensitive versus resistant cell lines.
Researchers analyzed whether specific molecular features, including glutaminase expression patterns and basal metabolite levels, could predict sensitivity to CB-839.
The most promising results were then tested in mouse models, including patient-derived xenografts that more closely mimic human tumors.
Finally, they evaluated whether CB-839 enhanced the effectiveness of standard chemotherapy (paclitaxel).
The experimental findings revealed a consistent pattern: basal-like/triple-negative breast cancer cells were significantly more vulnerable to CB-839 than other subtypes 1 .
| Cancer Type | Sensitivity to CB-839 | Glutaminase Activity | Glutamine Dependence |
|---|---|---|---|
| Triple-Negative/Basal-like | High | Elevated | Strong |
| ER-Positive (Luminal) | Low to Moderate | Lower | Weak |
| HER2-Positive | Variable | Variable | Moderate |
| Parameter | Before Treatment | After CB-839 | Change |
|---|---|---|---|
| Glutamine Consumption | High | Low | -85% |
| Glutamate Production | High | Low | -90% |
| Oxygen Consumption | High | Moderate | -50% |
| Glutathione Levels | Normal | Low | -70% |
| TCA Cycle Intermediates | Abundant | Depleted | -60% to -80% |
By blocking glutamate production, CB-839 starved the TCA cycle of critical fuel, reducing energy production essential for cancer cell survival 1 .
Depletion of glutathione left cancer cells vulnerable to oxidative damage, triggering programmed cell death 7 .
Limited availability of nitrogen-containing compounds impaired the synthesis of new DNA and proteins, halting cancer cell proliferation 5 .
| Cancer Model | CB-839 Alone | CB-839 + Paclitaxel | Tumor Characteristics |
|---|---|---|---|
| Patient-Derived TNBC | Significant growth inhibition | Enhanced effect | Highly glutamine-dependent |
| JIMT-1 (HER2+) | Moderate inhibition | Strong synergy | Basal-like features |
Perhaps most notably, the research team identified elevated GAC expression as a potential biomarker for CB-839 sensitivity, raising the possibility of eventually selecting patients most likely to benefit from this treatment 1 .
| Research Tool | Function/Application | Relevance to CB-839 Research |
|---|---|---|
| CB-839 (Telaglenastat) | Selective, orally available GLS1 inhibitor | Primary investigational drug; targets both GAC and KGA glutaminase variants |
| CellTiter-Glo 2.0 Assay | Measures cell viability based on ATP levels | Quantifies anti-proliferative effects of CB-839 |
| Metabolomics Platforms | Analyzes levels of metabolites (glutamine, glutamate, TCA intermediates) | Documents metabolic consequences of glutaminase inhibition |
| Seahorse Analyzer | Measures oxygen consumption rate (OCR) and extracellular acidification rate (ECR) | Assesses mitochondrial function and energy metabolism changes |
| Patient-Derived Xenografts | Human tumors grown in immunocompromised mice | Tests CB-839 efficacy in clinically relevant models |
| SLC1A5 Inhibitors | Blocks glutamine transport into cells | Used in combination studies to completely block glutamine utilization |
While CB-839 shows promise as a single agent in specific contexts, researchers recognized that cancers often develop adaptive resistance mechanisms. This insight led to the strategic development of rational combination therapies designed to attack cancer cells on multiple fronts simultaneously:
Preclinical models demonstrated that CB-839 significantly enhanced the efficacy of this standard chemotherapy drug in basal-like HER2+ breast cancer models 1 .
Research in other cancers has shown that glutaminase inhibition can overcome resistance to various targeted therapies 7 .
Emerging evidence suggests that modifying tumor metabolism can enhance immune cell function within the tumor microenvironment 5 .
Recent research has revealed another fascinating dimension of glutamine metabolism—its role in the tumor microenvironment. Cancer-associated fibroblasts (CAFs), which form a supportive stroma around tumors, have been found to secrete nutrients that help cancer cells survive metabolic stress. CB-839 can disrupt this supportive relationship, making it harder for cancer cells to adapt to nutrient deprivation 2 . This suggests that part of CB-839's effectiveness may come from its ability to target not just the cancer cells themselves, but the entire ecosystem that supports tumor growth.
The investigation into CB-839 represents a fascinating convergence of cancer metabolism research, drug development, and biomarker discovery. By targeting the unique metabolic addiction of basal-like breast cancer cells, this approach offers a promising path against a subtype that has historically lacked specific therapeutic options. While challenges remain—including identifying the patients most likely to benefit and optimizing combination strategies—the research highlights the importance of understanding cancer at a metabolic level.
As clinical trials continue to evaluate CB-839 in various combinations, the dream of using metabolic inhibitors as a core component of cancer therapy moves closer to reality. The story of CB-839 reminds us that sometimes, the most effective way to fight cancer isn't necessarily through direct confrontation, but by strategically cutting off its fuel supply and letting it succumb to its own metabolic dependencies.
References will be added here in the required format.